IXICO raises revenue guidance on expanded pipeline

IXICO PLC (LSE:IXI, OTC:PHYOF) CEO Bram Goorden talked with Proactive's Stephen Gunnion about the company’s expansion strategy and financial outlook for 2025. Goorden confirmed that IXICO expects full-year revenues of £6.3 million, reflecting a 5% uplift over prior guidance and a 9% increase compared to 2024. The company maintains a strong cash position due to its earlier capital raise, he noted. Goorden highlighted continued momentum in diversifying IXICO’s portfolio beyond Huntington’s disease, moving into Alzheimer’s and Parkinson’s disease. He explained, “We also see our pipeline and our order book now showing more of these projects.” Other growth drivers included deeper collaboration with clients and IXICO’s role in securing FDA approval for Fujirebio Diagnostics’ first Alzheimer’s blood-based biomarker test in the US. The CEO described this as the beginning of a broader multimodality strategy and anticipated further contracts stemming from these capabilities. Looking ahead, IXICO plans to secure at least one major data partnership to extend its technology platform to new customers and expects additional wins from its expanded US footprint. Visit Proactive’s YouTube channel for more videos, and don’t forget to give this video a like, subscribe to the channel, and enable notifications for future content. #IXICO #AlzheimersResearch #ParkinsonsDisease #Biomarkers #Neuroscience #ClinicalTrials #FDAApproval #DataPartnerships #BiotechNews #ProactiveInvestors